Bempid is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C.
Bempedoic Acid is an adenosine triphosphate-citrate lyase (ACL) inhibitor that lowers low-density lipoprotein cholesterol (LDL-C) by inhibition of cholesterol synthesis in the liver. ACL is an enzyme upstream of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase in the cholesterol biosynthesis pathway. Bempedoic acid and its active metabolite, ESP15228, require coenzyme A (CoA) activation by very long-chain acyl-CoA synthetase 1 (ACSVL1) to ETC-1002-CoA and ESP15228-CoA, respectively. ACSVL1 is expressed primarily in the liver. Inhibition of ACL by ETC-1002-CoA results in decreased cholesterol synthesis in the liver and lowers LDL-C in blood via upregulation of low-density lipoprotein receptors.
Administer 180 mg orally once daily with or without food.
Upper respiratory tract infection Muscle spasms Hyperuricemia Back pain Abdominal pain or discomfort Bronchitis Pain in extremity Anemia Elevated liver enzymes
Always consult a registered doctor before taking any medicine. This information is for general knowledge only.
Simvastatin : Avoid concomitant use of Bempid with simvastatin greater than 20 mg. Pravastatin : Avoid concomitant use of Bempid with pravastatin greater than 40 mg.
Elevations in serum uric acid have occurred. Assess uric acid levels periodically as clinically indicated. Monitor for signs and symptoms of hyperuricemia, and initiate treatment with urate-lowering drugs as appropriate. Tendon rupture has occurred. Discontinue Bempid at the first sign of tendon rupture. Avoid Bempid in patients who have a history of tendon disorders or tendon rupture.